Susquehanna International Group, LLP Ngm Biopharmaceuticals Inc Call Options Transaction History

Susquehanna International Group, LLP

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2023 May 16, 2023	SELL	$3.72 - $5.4 $189,348 - $274,860	-50,900 Reduced 79.78%	12,900 $52,000
Q4 2022 Feb 14, 2023	SELL	$3.41 - $12.93 $121,055 - $459,015	-35,500 Reduced 35.75%	63,800 $320,000
Q3 2022 Nov 14, 2022	BUY	$12.59 - $17.67 $696,227 - $977,151	55,300 Added 125.68%	99,300 $1.3 Million
Q2 2022 Aug 15, 2022	BUY	$10.58 - $17.5 $465,520 - $770,000	44,000 New	44,000 $564,000
Q4 2021 Feb 14, 2022	SELL	$17.26 - $22.02 $291,694 - $372,138	-16,900 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$20.15 - $26.19 $181,350 - $235,710	-9,000 Reduced 34.75%	16,900 $355,000
Q1 2021 May 17, 2021	BUY	$24.99 - $31.93 $362,355 - $462,985	14,500 Added 127.19%	25,900 $753,000
Q4 2020 Feb 16, 2021	BUY	$16.21 - $31.44 $184,794 - $358,416	11,400 New	11,400 $345,000

2.6M

300

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.